Perlmutter Cancer Center

If you have been diagnosed with cancer of the urinary system (urothelial cancer, including cancer of the bladder, renal pelvis, ureter or urethra) that has spread to nearby tissues or to other areas of the body and you have been treated with a CPI as defined as a PD-1 inhibitor or PD-L1 inhibitor (including, but not limited to: atezolizumab, pembrolizumab, durvalumab, avelumab, and nivolumab), you may qualify for this study. The main goal of this phase II study is to find out if the investigational drug, enfortumab vedotin, will treat urothelial cancer in patients and who have already been treated with an immune checkpoint inhibitor (CPI) drug.